Omics Gaucher Study: Multiomic Approach

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

25 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-06

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to investigate the transcriptomic and metabolomic changes in blood, plasma and isolated monocytes from Gaucher patients and healthy controls.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of Omics Methods to Classify Variations of Uncertain Significance and Improve Diagnosis of Neurogenetic Diseases

NCT06955624

Neurogenetic Diseases

RECRUITING NA

Identification of the Genetic Causes of Rare Diseases With Negative Exome Findings

NCT04315727

Rare Diseases Genetic Predisposition to Disease

RECRUITING NA

NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing

NCT01969370

Cancer Cardiovascular Disease Neurologic Dysfunction +2 more

COMPLETED NA

Investigating the Feasibility and Implementation of Whole Genome Sequencing in Patients With Suspected Genetic Disorder

NCT03829176

Hereditary Disease Genetic Predisposition to Disease

COMPLETED NA

Diagnostic Value of Exome/ Genome Sequencing, Conventional Methods in Rare Diseases and Familial Tumor Syndromes

NCT04731857

Rare Diseases Genetic Predisposition

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Gaucher disease is one of the most common lysosomal storage disorders (LSD) and is an autosomal recessive inherited disorder, primed by mutation in the GBA1 gene which leads to a deficiency in β-glucocerebrosidase (GCase) activity and accumulation of its substrate glucosylceramide (GluCer)/-sphingosine (GluSph). The macrophages are the main cell type exhibiting a Gaucher disease phenotype. The large accumulation of GluCer and to a lesser extent that of GluSph lead to dysfunction in organs such as spleen, liver, bone marrow, and lungs.

However, a validated, reproducible, and broadly applicable tool to classify Gaucher Disease at any stage of the disease is still missing.

The development of new technologies, such as genomic analysis by next generation sequencing (NGS) and other "omics technologies," has advanced the molecular understanding and diagnosis of Rare Diseases

The current study will analyze the transcriptional and metabolomic profiles in blood, plasma and isolated monocytes from Gaucher patients and healthy controls with the aim to compare these profiles and to define how much a patient profile differs from a healthy one.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gaucher Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gaucher Type 1

* The participant was diagnosed with Gaucher type 1 disease
* Adults only

Genetic testing and Omics analysis

Intervention Type OTHER

Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics

Gaucher Type 3

* The participant was diagnosed with Gaucher type 3 disease
* Adults only

Genetic testing and Omics analysis

Intervention Type OTHER

Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics

Healthy Volunteer

* Healthy participants
* Adults only

Genetic testing and Omics analysis

Intervention Type OTHER

Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genetic testing and Omics analysis

Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Gaucher Type 1 participants:

* Informed consent
* The participant is older than 18 years old
* The participant was diagnosed with Gaucher Type 1 disease

Gaucher Type 3 participants:

* Informed consent
* The participant is older than 18 years old
* The participant was diagnosed with Gaucher type 3 disease

Healthy participants:

* Informed consent
* The participant is older than 18 years old
* Healthy participants

Exclusion Criteria

Gaucher Type I participants:

* The participant had any other clinically significant disease
* The participant had a recent (within 14 days) acute infection and/or vaccination

Gaucher Type 3 participants:

* Diagnosis of a significant CNS disease or cardiovascular disease other than Gaucher type 3
* The participant had a recent (within 14 days) acute infection and/or vaccination

Healthy participants:

* The participant had a recent (within 14 days) acute infection and/or vaccination

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes